GlaxoSmithKline Services Unlimited RE: Comment on Potential Amendment to Federal Rule of Evidence 702
View the document here.
Previous
Previous
Jonathan Redgrave, Redgrave LLP: Re: Submission to Advisory Committee on Civil Rules in Support of Examining Rulemaking Regarding Privilege Logs
Next
Next